Mature results from Medivir’s phase 1b / 2a open label trial of fostrox + Lenvima® confirm improved outcomes in second-line advanced liver cancer with a median time to progression (TTP) of 10.9 months1 (4.1 – 18.1). The results showed an objective response (ORR) of 24%, and a median…